(An open ended equity scheme investing in
Pharma and Healthcare sector)
(An open ended equity scheme investing in
Pharma and Healthcare sector)
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
NAV Details (As on April 30, 2026)| Regular IDCW | : ₹ 9.4451 |
| Regular Growth | : ₹ 9.4451 |
| Direct IDCW | : ₹ 9.5893 |
| Direct Growth | : ₹ 9.5893 |
Benchmark Index (Tier 1)BSE Healthcare TRI
Date of AllotmentJune 27, 2025
Fund Manager^ | Fund Manager | Managing fund since | Experience |
| Mr. Rohan Korde | 01-May-26 | 21 years |
Load Structure
Exit Load: • Redemption/ switch out of units upto 10% of the
units allotted before 1 year from date of allotment- Exit
load -NIL. • For redemption/switch out of units above 10%
of units allotted within 1 year from the date of allotment-
1.00% of applicable NAV. • For redemption/switch out of
units after 1 year from the date of allotment-Nil.
For detailed load structure please refer Scheme
Information Document.
Minimum Application Amount:
₹ 1,000 and in multiples of ₹ 1
thereafter.
Minimum Additional Purchase Amount:₹ 1,000 and in
multiples of ₹ 1 thereafter.
| Monthly AAUM## As on April 30, 2026 | : ₹ 520.67 Crores |
| AUM## As on April 30, 2026 | : ₹ 530.21 Crores |
## including inter-scheme Investments, if any, by other schemes of Baroda BNP Paribas Mutual Fund, as may be applicable
| NAME OF INSTRUMENT | % of Net Assets | |
| Pharmaceuticals & Biotechnology | 67.79% | |
| ✔Sun Pharmaceutical Industries Limited | 9.38% | |
| ✔Lupin Limited | 6.09% | |
| ✔IPCA Laboratories Limited | 5.34% | |
| ✔Abbott India Limited | 5.28% | |
| ✔Torrent Pharmaceuticals Limited | 5.13% | |
| ✔Laurus Labs Limited | 4.78% | |
| ✔JB Chemicals & Pharmaceuticals Limited | 4.24% | |
| ✔AstraZeneca Pharma India Limited | 4.03% | |
| Emcure Pharmaceuticals Limited | 3.44% | |
| Glenmark Pharmaceuticals Limited | 2.72% | |
| Aurobindo Pharma Limited | 2.62% | |
| Gland Pharma Limited | 2.09% | |
| Divi's Laboratories Limited | 2.07% | |
| Ajanta Pharma Limited | 1.86% | |
| Acutaas Chemicals Limited | 1.76% | |
| Concord Biotech Limited | 1.29% | |
| Mankind Pharma Limited | 1.27% | |
| Dr. Reddy's Laboratories Limited | 1.25% | |
| Cipla Limited | 1.11% | |
| Procter & Gamble Health Limited | 1.08% | |
| Cohance Lifesciences Limited | 0.96% | |
| Healthcare Services | 17.88% | |
| ✔Fortis Healthcare Limited | 4.35% | |
| ✔Apollo Hospitals Enterprise Limited | 4.32% | |
| Aster DM Healthcare Limited | 2.97% | |
| Dr. Lal Path Labs Limited | 2.58% | |
| Nephrocare Health Services Ltd | 1.50% | |
| Metropolis Healthcare Limited | 1.12% | |
| Jupiter Life Line Hospitals Limited | 1.04% | |
| Insurance | 7.29% | |
| SBI Life Insurance Company Limited | 3.43% | |
| ICICI Prudential Life Insurance Company Limited | 2.81% | |
| Max Financial Services Limited | 1.05% | |
| Retailing | 1.64% | |
| MedPlus Health Services Limited | 1.64% | |
| IT - Services | 1.56% | |
| Inventurus Knowledge Solutions Limited | 1.56% | |
| Healthcare Equipment & Supplies | 1.09% | |
| Poly Medicure Limited | 1.09% | |
| LESS THAN 0.75% EXPOSURE | 0.01% | |
| TOTAL EQUITY HOLDING | 97.26% | |
| Total Fixed Income Holdings | ||
| TREPS, Cash & Other Net Current Assets | 2.74% | |
| GRAND TOTAL | 100.00% | |
Investment in Top 10 scrips constitutes 52.94% of the portfolio
The scheme currently does not have Distribution History.
| BER - Regular Plan (%) | 2.09% |
| BER - Direct Plan (%) | 0.62% |
| Portfolio Turnover Ratio | 0.69 |
The Total Expense Ratio (TER) is the sum of the Base Expense Ratio (BER), brokerage fees, transaction costs, and statutory levies.
| No of Stocks | 34 |
| Portfolio RoE (%) | 16.50 |
| EPS Growth (%) | 41.94 |
➤ Long term capital appreciation.
➤ Investing predominantly in equity and equity related instruments of Pharma and Healthcare companies
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.
^^Riskometer For Scheme: basis it’s portfolio, ^Riskometer For Benchmark (BSE Healthcare TRI): basis it’s constituents; As on April 30, 2026
For complete portfolio, kindly refer the website https://www.barodabnpparibasmf.in/
* refer Glossary page
Mutual Fund investments are subject to market risks, read all scheme related documents carefully.